These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 6144029)

  • 1. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics.
    Christensen AV; Arnt J; Hyttel J; Larsen JJ; Svendsen O
    Life Sci; 1984 Apr; 34(16):1529-40. PubMed ID: 6144029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological differentiation of dopamine D-1 and D-2 antagonists after single and repeated administration.
    Christensen AV; Arnt J; Svendsen O
    Psychopharmacology Suppl; 1985; 2():182-90. PubMed ID: 2860659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    Hyttel J; Christensen AV
    J Neural Transm Suppl; 1983; 18():157-64. PubMed ID: 6135740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity.
    Arnt J
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):97-104. PubMed ID: 2864641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions.
    Arnt J; Hyttel J
    Eur J Pharmacol; 1984 Jul; 102(2):349-54. PubMed ID: 6148252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats.
    Arnt J; Hyttel J; Bach-Lauritsen T
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):319-24. PubMed ID: 2879412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Psychopharmacology (Berl); 1983; 81(3):199-207. PubMed ID: 6139838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scopolamine modulates apomorphine-induced behavior in rats treated with haloperidol or SCH 23390.
    Butkerait P; Friedman E
    Eur J Pharmacol; 1988 Mar; 148(2):269-72. PubMed ID: 2897925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions.
    Arnt J
    Life Sci; 1985 Aug; 37(8):717-23. PubMed ID: 3927097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-2 dopamine antagonist-like effects of SCH 23390 on A9 and A10 dopamine neurons.
    Goldstein JM; Litwin LC; Sutton EB; Malick JB
    Life Sci; 1987 Mar; 40(11):1039-44. PubMed ID: 2950291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the dopamine D-1 antagonist SCH 23390 on water intake, water-rewarded operant responding and apomorphine-induced decrease of water intake in rats.
    Ljungberg T
    Pharmacol Biochem Behav; 1989 Jul; 33(3):709-12. PubMed ID: 2685829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatum in vitro.
    Plantjé JF; Hansen HA; Daus FJ; Stoof JC
    Eur J Pharmacol; 1984 Oct; 105(1-2):73-83. PubMed ID: 6208045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SCH 23390--a selective dopamine D-1 receptor antagonist with putative 5-HT1 receptor agonistic activity.
    Skarsfeldt T; Larsen JJ
    Eur J Pharmacol; 1988 Apr; 148(3):389-95. PubMed ID: 2968272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics.
    Arnt J; Christensen AV
    Eur J Pharmacol; 1981 Jan; 69(1):107-11. PubMed ID: 6110555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.